Selegiline Transdermal System for the Treatment of Cocaine Dependence - 1

• Status: Completed
• Trial end date: 1969-12-31
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to evaluate the Selegiline Transdermal System for the treatment of cocaine dependence.

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: National Institute on Drug Abuse (NIDA)
• Collaborator: Somerset Pharmaceuticals
• Treatments: Cocaine; Selegiline

Criteria

Inclusion Criteria:

• Male/Female

• At least 18 years of age

• DSM-4 diagnosis of cocaine dependence

• Ability to understand and provide written consent

• Female subjects must use acceptable birth control

Exclusion Criteria:

• Additional Criteria available during the screening process at the site.